The novel AR inhibitor Caficrestat showed promising results in the treatment of patients with COVID-19 and co-morbid diabetes mellitus and heart disease: In these patients, Caficrestat reduced mortality and the length of hospitalization, although the results did not reach significance [74]. This evidence concerns the gene AR and heart disorder.